Shots:
Repligen has entered into a definitive agreement to acquire BioLife
Repligen will acquire BioLife for an enterprise value of ~$1.5B, with BioLife stockholders receiving $11.25 per share in cash plus 0.1442 Repligen shares, representing total consideration of $31/share, comprising 64% stock & 36% cash
Acquisition is expected to fast-track Repligen’s leadership & customer solutions…
